Enhancing Health System Initiatives:
Utilizing Clinical Advances to Optimize the Diagnosis and Treatment of Prostate Cancer
Supported by educational grants from Astellas and Medivation, Inc. a Pfizer company, AstraZeneca, and Genomic Health.
OVERVIEW
Nonmetastatic castrate-resistant prostate cancer (nmCRPC) is defined as a clinical state where patients, despite achieving castrate levels of testosterone with androgen deprivation therapy (ADT), exhibit progressive disease as determined by biochemical evidence of recurrence (ie, rising prostate-specific antigen [PSA] levels), with no evidence of radiographic metastases. As a newly defined disease state associated with a degree of clinical uncertainty, many clinicians face challenges managing patients with nmCRPC in practice. This is particularly true in light of growing “PSA anxiety” that some patients experience, who worry as their PSA levels rise and want to know what their treatment options are. Challengingly, this patient population is clinically heterogeneous, with patients presenting with varying degrees of disease aggressiveness and prognosis. Recently completed and ongoing studies have established the role of antiandrogen receptor (AR) agents for treatment of patients with nmCRPC, with 2 agents recently receiving US Food and Drug Administration approval as the first, and currently only, treatments for this population. Despite the promising study results, many questions remain regarding their appropriate use in nmCRPC patients. These interactive case modules will highlight our current understanding of nmCRPC patients, the current clinical data for anti-AR therapies for nmCRPC, how to identify appropriate patients, managing associated toxicities, effect on subsequent therapy options, and expected outcomes.
GOAL
The goal of this program is for academic and community urologists, radiation and medical oncologists, oncologic surgeons, residents, fellows, nurse practitioners, physician assistants, nurses, and other allied healthcare professionals interested in the treatment and management of PC to obtain the necessary information to effectively use anti-AR therapy in appropriate nmCRPC patients.
TARGET AUDIENCE
This activity is intended for academic and community urologists, radiation and medical oncologists, oncologic surgeons, residents, fellows, nurse practitioners, physician assistants, nurses, and other allied healthcare professionals interested in the treatment and management of prostate cancer. No prerequisites required.
LEARNING OBJECTIVES
After completing this activity, participants will demonstrate the ability to:
CE INFORMATION
Accredidation Statement
In support of improving patient care, MedStar Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) and the American Academy of PAs (AAPA), to provide continuing education for the healthcare team.
Credit Designation Statement
This activity was planned by and for the healthcare team, and learners will receive 0.5 interprofessional Continuing Education (IPCE) credits for learning and change.
The estimated time to complete this activity: 30 minutes.
Release date: December 19, 2018. Expiration date: December 19, 2019.
ACTIVITY CHAIR
Ross E. Krasnow, MD, MPH
MedStar Washington Hospital Center
Washington, DC
DISCLOSURES
No faculty members have indicated that they have any financial interests or relationships with a commercial entity.
ACTIVITY
Instructions
The following is an interactive case activity designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited preassessment, the interactive case modules, and a CE postassessment and evaluation. All 3 sections must be completed to receive CE credit. A certificate of participation will be available online immediately following successful completion of the activity.
Table of Contents
Preassessment
Enhancing Health System Initiatives:
Utilizing Clinical Advances to Optimize the Diagnosis and Treatment of Prostate Cancer – Clinical Cases in Prostate Cancer
Ross E. Krasnow, MD
Postassessment and Evaluation
